Date:9/26/2007

differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the timing, success and cost of preclinical research and clinical studies, (ii) the timing, acceptability and review periods for regulatory filings, (iii) the availability of corporate partners, (iv) uncertainties relating to patent protection and intellectual property rights of third parties, (v) the impact of competitive products and technological changes, (vi) the availability of capital and the cost of capital, (vii) other vagaries in the biotechnology industry and (viii) other risks. ChemoCentryx undertakes no obligation to update or revise any forward-looking statements.

'/>"/>

SOURCE ChemoCentryx, Inc. Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
2. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
3. Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived Tissue
4. pFB-ERV: Retroviral Delivery of the Ecdysone Receptor Proteins
5. Gene-Specific Primers for NMDA Receptor Subunits
6. TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins
7. Quantification of the Purinergic Receptor P2X3 using ICAT and Orthogonal 2D LC-MS/MS with an Ion Trap Mass Spectrometer
8. Isolation of Low Molecular Weight Digestion Products of the Human Platelet Thromboxane A2 Receptor, Rev A
9. Performance of Ad-A-Gene EGFP-Glucocorticoid Receptor (EGFP-GCCR): an adenoviral vector gene delivery system
10. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
11. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System